{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:29:59Z","timestamp":1777598999972,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13300-021-01079-x","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T06:03:28Z","timestamp":1622181808000},"page":"1861-1870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide\u00a01 Receptor Agonists in Chinese Patients with Type\u00a02 Diabetes Mellitus"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct01128205","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaoling","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"issue":"2","key":"1079_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/ijerph17020596","volume":"17","author":"ME Hossain","year":"2020","unstructured":"Hossain ME, Uddin S, Khan A, Moni MA. A framework to understand the progression of cardiovascular disease for type\u00a02 diabetes mellitus patients using a network approach. Int J Environ Res Public Health. 2020;17(2):596.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1079_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2337\/dc15-2237","volume":"39","author":"RJ Smith","year":"2016","unstructured":"Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type\u00a02 diabetes: time to reassess? Diabetes Care. 2016;39(5):738\u201342.","journal-title":"Diabetes Care"},{"issue":"14","key":"1079_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMp1309610","volume":"369","author":"WR Hiatt","year":"2013","unstructured":"Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs\u2013insights from the rosiglitazone experience. N Engl J Med. 2013;369(14):1285\u20137.","journal-title":"N Engl J Med"},{"issue":"9681","key":"1079_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type\u00a02 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125\u201335.","journal-title":"Lancet"},{"issue":"9493","key":"1079_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type\u00a02 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"12","key":"1079_CR6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/pds.3874","volume":"24","author":"D Mendes","year":"2015","unstructured":"Mendes D, Alves C, Batel-Marques F. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2015;24(12):1259\u201370.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10193","key":"1079_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type\u00a02 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"1","key":"1079_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.13028","volume":"20","author":"HC Gerstein","year":"2018","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"13","key":"1079_CR9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"key":"1079_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2017.02.005","volume":"187","author":"RJ Mentz","year":"2017","unstructured":"Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017;187:1\u20139.","journal-title":"Am Heart J"},{"issue":"4","key":"1079_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"1079_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","volume":"166","author":"SP Marso","year":"2013","unstructured":"Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823-830.e825.","journal-title":"Am Heart J"},{"issue":"19","key":"1079_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10","key":"1079_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type\u00a02 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1079_CR15","doi-asserted-by":"crossref","unstructured":"Cardiovascular Disease and Risk Management. Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111\u2013s134.","DOI":"10.2337\/dc20-S010"},{"issue":"Suppl 1","key":"1079_CR16","first-page":"S98","volume":"43","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2020","unstructured":"Pharmacologic Approaches to Glycemic Treatment. Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98-s110.","journal-title":"Diabetes Care"},{"issue":"10157","key":"1079_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type\u00a02 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"9","key":"1079_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"23","key":"1079_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type\u00a02 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"3","key":"1079_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1602\/neurorx.1.3.363","volume":"1","author":"AD Siderowf","year":"2004","unstructured":"Siderowf AD. Evidence from clinical trials: can we do better? NeuroRx. 2004;1(3):363\u201371.","journal-title":"NeuroRx"},{"issue":"6","key":"1079_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/dom.13649","volume":"21","author":"KS Boye","year":"2019","unstructured":"Boye KS, Riddle MC, Gerstein HC, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type\u00a02 diabetes population in the United States. Diabetes Obes Metab. 2019;21(6):1299\u2013304.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1079_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/dom.13962","volume":"22","author":"V Sciannameo","year":"2020","unstructured":"Sciannameo V, Berchialla P, Orsi E, et al. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: the case of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2020;22(5):817\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1079_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jdiacomp.2017.10.016","volume":"32","author":"S Kou","year":"2018","unstructured":"Kou S, Cao JY, Yeo S, Holmes-Walker DJ, Lau SL, Gunton JE. Ethnicity influences cardiovascular outcomes and complications in patients with type\u00a02 diabetes. J Diabetes Complic. 2018;32(2):144\u20139.","journal-title":"J Diabetes Complic"},{"issue":"10","key":"1079_CR24","doi-asserted-by":"publisher","first-page":"925.e911","DOI":"10.1016\/j.amjmed.2013.02.035","volume":"126","author":"L Ji","year":"2013","unstructured":"Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type\u00a02 diabetes patients. Am J Med. 2013;126(10):925.e911-922.","journal-title":"Am J Med"},{"issue":"11","key":"1079_CR25","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/jch.13675","volume":"21","author":"YQ Zhang","year":"2019","unstructured":"Zhang YQ, Li Y, Dong YG, et al. A nationwide assessment of blood pressure control and the associated factors in Chinese type\u00a02 diabetes mellitus patients. J Clin Hypertens (Greenwich). 2019;21(11):1654\u201363.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1079_CR26","unstructured":"World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance, World Bank; 1999."},{"key":"1079_CR27","unstructured":"Chinese Diabetes Society. China guideline for type\u00a02 diabetes (2007 edition). Zhonghua Yi Xue Za Zhi . 2008;18(88):1227\u20131246."},{"issue":"2","key":"1079_CR28","doi-asserted-by":"publisher","first-page":"e0116970","DOI":"10.1371\/journal.pone.0116970","volume":"10","author":"Q Xie","year":"2015","unstructured":"Xie Q, Hao CM, Ji L, et al. ACEI\/ARB underused in patients with type\u00a02 diabetes in Chinese population (CCMR-3B study). PLoS ONE. 2015;10(2):e0116970.","journal-title":"PLoS ONE"},{"issue":"1","key":"1079_CR29","doi-asserted-by":"publisher","first-page":"e0144179","DOI":"10.1371\/journal.pone.0144179","volume":"11","author":"X Zhou","year":"2016","unstructured":"Zhou X, Ji L, Ran X, et al. Prevalence of obesity and its influence on achievement of cardiometabolic therapeutic goals in Chinese type\u00a02 diabetes patients: an analysis of the nationwide, cross-sectional 3b study. PLoS ONE. 2016;11(1):e0144179.","journal-title":"PLoS ONE"},{"issue":"6","key":"1079_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00592-017-0981-2","volume":"54","author":"Y Huang","year":"2017","unstructured":"Huang Y, Li J, Zhu X, et al. Relationship between healthy lifestyle behaviors and cardiovascular risk factors in Chinese patients with type\u00a02 diabetes mellitus: a subanalysis of the CCMR-3B STUDY. Acta Diabetol. 2017;54(6):569\u201379.","journal-title":"Acta Diabetol"},{"key":"1079_CR31","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/. Accessed Jan 8."},{"issue":"7","key":"1079_CR32","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/dom.13710","volume":"21","author":"W Hinton","year":"2019","unstructured":"Hinton W, Feher M, Munro N, Walker M, de Lusignan S. Real-world prevalence of the inclusion criteria for the LEADER trial: data from a national general practice network. Diabetes Obes Metab. 2019;21(7):1661\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1079_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jdi.12305","volume":"6","author":"YM Cho","year":"2015","unstructured":"Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015;6(5):495\u2013507.","journal-title":"J Diabetes Investig"},{"issue":"10","key":"1079_CR34","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/dom.12293","volume":"16","author":"YG Kim","year":"2014","unstructured":"Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):900\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1079_CR35","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2337\/dc07-1525","volume":"31","author":"PA Vel\u00e1squez-Mieyer","year":"2008","unstructured":"Vel\u00e1squez-Mieyer PA, Cowan PA, P\u00e9rez-Faustinelli S, et al. Racial disparity in glucagon-like peptide 1 and inflammation markers among severely obese adolescents. Diabetes Care. 2008;31(4):770\u20135.","journal-title":"Diabetes Care"},{"issue":"4","key":"1079_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4093\/dmj.2018.0070","volume":"43","author":"YM Kang","year":"2019","unstructured":"Kang YM, Cho YK, Lee J, et al. Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a meta-analysis of cardiovascular outcome trials. Diabetes Metab J. 2019;43(4):410\u201321.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"1079_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type\u00a02 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:57:20Z","timestamp":1628611040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01079-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}